Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Asceneuron SA logo — Targeting the root cause of neurodegeneration

Asceneuron SA

Targeting the root cause of neurodegeneration

Founded 2012 Switzerland Lausanne, Switzerland 20 employees Series C Total: $130.00M Biotechnology, Health Care +1

General Information

Company Name Asceneuron SA
Founded Year 2012
Location Switzerland Lausanne, Switzerland
Founders / Decision Makers
Team member
Employees 20
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Asceneuron SA. To contact Asceneuron SA, visit asceneuron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Asceneuron SA compare?

A PDF of Asceneuron SA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Asceneuron SA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Asceneuron SA

Asceneuron SA is a Switzerland-based clinical stage biotech company with a focus on developing orally bioavailable therapeutics for neurodegenerative disorders. With the mission of targeting the root cause of neurodegeneration, Asceneuron's pipeline aims to address a wide range of neurodegenerative diseases such as orphan tauopathies, Alzheimer’s, and Parkinson’s disease. The company has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s disease and Alzheimer’s. Established in 2012, Asceneuron has garnered significant support from a renowned syndicate of investors including Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Kurma Partners. Their most recent Series C investment of $100.00M on 16 July 2024 saw participation from a diverse group of investors including Novo Holdings, OrbiMed, GlaxoSmithKline, MERL Ventures Fund, EQT Life Sciences, and Johnson & Johnson Innovation – JJDC, reflecting industry confidence in the company's potential. Asceneuron's dedication to addressing the significant unmet medical needs in neurodegenerative disorders and the strong backing from prominent investors position it as a notable player in the biotechnology and health care sectors. For more information, visit www.asceneuron.com.

Business keywords: Neurodegenerative Diseases, Biotech Company, Orphan Tauopathies, Alzheimer's Disease, Parkinson's Disease, Small Molecule Therapeutics, O-GlcNAcase Inhibitors, Clinical Stage Development, Neurofibrillary Tangles, Frontotemporal Dementia, Healthcare Innovation, Drug Discovery, Investment Syndicate, Neurological Disorders, Therapeutic Development

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $100.00M 8
Novo Holdings Sofinnova Partners OrbiMed
Novo Holdings, Sofinnova Partners +6
16 Jul 2024
Grant Undisclosed 1
The Michael J. Fox Foundation for Parkinson's Research
The Michael J. Fox Foundation for Parkinson's Research
04 May 2022
Grant Undisclosed 1
The Michael J. Fox Foundation for Parkinson's Research
The Michael J. Fox Foundation for Parkinson's Research
06 Oct 2016
Series A Fr.30.00M -
29 Sep 2015

Asceneuron SA Alternatives & Competitors

View All Alternatives
Asceneuron SA vs
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. United States

Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN

Grant
20 employees
Biotechnology, Health and Wellness
Asceneuron SA vs
Wren Therapeutics
Wren Therapeutics United Kingdom

Stopping the wave of neurodegeneration at its source

Venture round
34 employees
Biopharma, Biotechnology
Compare Asceneuron SA vs Wren Therapeutics
Asceneuron SA vs
Annovis Bio, Inc.
Annovis Bio, Inc. United States

Transforming how we treat Alzheimer’s, Parkinson’s, and beyond.

IPO
12 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Asceneuron SA

Targeting the root cause of neurodegeneration
Asceneuron SA was founded in 2012.
Asceneuron SA is headquartered in Lausanne, Switzerland.
Asceneuron SA operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Neurodegenerative Diseases, Biotech Company, Orphan Tauopathies and Alzheimer's Disease.
Asceneuron SA has approximately 20 employees.
Asceneuron SA has completed 4 funding rounds, raising a total of $130.00M. The latest funding stage is Series C.
Top alternatives and competitors to Asceneuron SA include CuraSen Therapeutics, Inc., Wren Therapeutics, Annovis Bio, Inc., Addex Therapeutics, Brainstorm Cell Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asceneuron SA and CuraSen Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Asceneuron SA, https://bouncewatch.com/company/asceneuron-sa, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes